Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease

被引:93
|
作者
Mocci, Giammarco [1 ]
Marzo, Manuela [2 ]
Papa, Alfredo [2 ]
Armuzzi, Alessandro [2 ]
Guidi, Luisa [2 ]
机构
[1] Brotzu Hosp, Gastroenterol Unit, I-09121 Cagliari, Italy
[2] Univ Cattolica Sacro Cuore, Internal Med & Gastroenterol Unit, Rome, Italy
来源
JOURNAL OF CROHNS & COLITIS | 2013年 / 7卷 / 10期
关键词
Anti-TNF; IBD; Skin manifestations; NECROSIS FACTOR THERAPY; FACTOR-ALPHA THERAPY; DRUG-INDUCED LUPUS; ADALIMUMAB-INDUCED PSORIASIS; NONMELANOMA SKIN CANCERS; RHEUMATOID-ARTHRITIS; CROHNS-DISEASE; INFUSION REACTIONS; AUTOIMMUNE-DISEASES; SERIOUS INFECTIONS;
D O I
10.1016/j.crohns.2013.01.009
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The clinical introduction of tumour necrosis factor (TNF) inhibitors has deeply changed the treatment of inflammatory bowel diseases (IBD). It has demonstrated impressive efficacy as compared to alternative treatments, allowing for the chance to achieve near-remission and long-term improvement in function and quality of life and to alter the natural history of Crohn's disease (CD) and ulcerative colitis (UC). As a consequence of longer follow-up periods the number of side effects which may be attributed to treatment with biologics is growing significantly. Cutaneous reactions are among the most common adverse reactions. These complications include injection site reactions, cutaneous infections, immune-mediated complications such as psoriasis and lupus-like syndrome and rarely skin cancers. We review the recent literature and draw attention to dermatological side effects of anti-TNF therapy of inflammatory bowel disease. (C) 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:769 / 779
页数:11
相关论文
共 50 条
  • [31] Inflammatory bowel disease and targeted oral anti-TNFα therapy
    Griffiths, Owen R.
    Landon, John
    Coxon, Ruth E.
    Morris, Keith
    James, Philip
    Adams, Rachel
    INFLAMMATORY DISORDERS, PT A, 2020, 119 : 157 - 198
  • [32] Current and future anti-TNF therapy for inflammatory bowel disease
    Osterman M.T.
    Lichtenstein G.R.
    Current Treatment Options in Gastroenterology, 2007, 10 (3) : 195 - 207
  • [33] Strategic Use of Immunosuppressants and Anti-TNF in Inflammatory Bowel Disease
    Louis, Edouard
    DIGESTIVE DISEASES, 2013, 31 (02) : 207 - 212
  • [34] Anti-TNF biologics in the treatment of chronic inflammatory bowel disease
    Nikolaus, S.
    Schreiber, S.
    INTERNIST, 2008, 49 (08): : 947 - +
  • [35] INFLAMMATORY BOWEL DISEASE: THE CONSEQUENCES OF ANTI-TNF THERAPY IN THE ELDERLY
    Ali, M.
    McClean, C.
    Zou, Y.
    Goh, J.
    GUT, 2016, 65 : A256 - A257
  • [36] Anti-TNFα in inflammatory bowel disease: from originators to biosimilars
    Zeng, Zhen
    Lin, Hao
    Jiang, Mingshan
    Yuan, Jing
    Li, Xi
    Jia, Yongbin
    Yang, Li
    Zhang, Hu
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [37] Safety of anti-TNF biologics in paediatric inflammatory bowel disease
    Ruemmele, Frank M.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (11): : 813 - 815
  • [38] ANTI-TNF INDUCED LYMPHOCYTOSIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Soufleris, Konstantinos
    Kafalis, Nikolaos
    Fasoulas, Konstantinos
    Pilpilidis, Ioannis
    Lazaraki, Georgia
    Markala, Dimitra
    Tzilves, Dimitris
    GASTROENTEROLOGY, 2019, 156 (06) : S635 - S635
  • [39] Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease
    Strik, A. S.
    Bots, S. J. A.
    D'Haens, G.
    Lowenberg, M.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (03) : 429 - 439
  • [40] Anti-TNF induced lupus in patients with inflammatory bowel disease
    Picardo, S.
    So, K.
    Venugopal, K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 109 - 109